ReviewAIDS (London, England)2012
Antiviral agents and HIV prevention: controversies, conflicts, and consensus.
Review in AIDS (London, England), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 1 synthesis or guideline pooled it, 99 citations in OpenAlex.
- HIV treatment as prevention: optimising the impact of expanded HIV treatment programmes.PLoS medicine · 2012Pooled it
- HIV disease progression in seroconvertors from the CAPRISA 004 tenofovir gel pre-exposure prophylaxis trial.Journal of acquired immune deficiency syndromes (1999) · 2015Trial
- The biobehavioral Women's Health CoOp in Pretoria, South Africa: study protocol for a cluster-randomized design.BMC public health · 2014Trial
- A randomized trial of a behavioral intervention for high risk substance-using MSM.AIDS and behavior · 2013Trial
- Can combination prevention strategies reduce HIV transmission in generalized epidemic settings in Africa? The HPTN 071 (PopART) study plan in South Africa and Zambia.Journal of acquired immune deficiency syndromes (1999) · 2013Trial
- Robustness of viral load over CD4 cell count in measuring the quality of life of people with HIV at second line regimen in Amhara region.Scientific reports · 2025Article
- Mental health, substance use, and risky sexual behaviors among women living with HIV.Journal of nursing scholarship : an official publication of Sigma Theta Tau International Honor Society of Nursing · 2023Article
- Dynamics of the Decay of Human Immunodeficiency Virus (HIV) RNA and Distribution of Bictegravir in the Genital Tract and Rectum in Antiretroviral-naive Adults Living With HIV-1 Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (Spanish HIV/AIDS Research Network, PreEC/RIS 58).Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021Article
- Sexual risk taking and the HIV care continuum in an online sample of men who have sex with men.AIDS care · 2018Article
- Previously Diagnosed HIV-Positive Persons: The Role of Centers for Disease Control and Prevention-Funded HIV Testing Programs in Addressing Their Needs.Sexually transmitted diseases · 2018Article
- When are declines in condom use while using PrEP a concern? Modelling insights from a Hillbrow, South Africa case study.Journal of the International AIDS Society · 2017Article
- Tenofovir alafenamide and elvitegravir loaded nanoparticles for long-acting prevention of HIV-1 vaginal transmission.AIDS (London, England) · 2017Article
- Nanoparticle Encapsulation for Antiretroviral Pre-Exposure Prophylaxis.Journal of nanotechnology and materials science · 2017Article
- Sexual Behaviors and Transmission Risks Among People Living with HIV: Beliefs, Perceptions, and Challenges to Using Treatments as Prevention.Archives of sexual behavior · 2016Article
- A mixed-methods study on the acceptability of using eHealth for HIV prevention and sexual health care among men who have sex with men in China.Journal of medical Internet research · 2015Article
- Elevated urinary leukocyte esterase as a potential surrogate marker for HIV sexual transmission risks in men receiving antiretroviral therapy.International journal of STD & AIDS · 2015Article
- Evaluating respondent-driven sampling as an implementation tool for universal coverage of antiretroviral studies among men who have sex with men living with HIV.Journal of acquired immune deficiency syndromes (1999) · 2015Article
- Homosexual men in HIV serodiscordant relationships: implications for HIV treatment as prevention research.Journal of the International AIDS Society · 2015Article
- HIV sexual transmission risks in the context of clinical care: a prospective study of behavioural correlates of HIV suppression in a community sample, Atlanta, GA, USA.Journal of the International AIDS Society · 2015Article
- Strategies for preventing mucosal cell-associated HIV transmission.The Journal of infectious diseases · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Antiviral agents can be used to prevent HIV transmission before exposure as preexposure prophylaxis (PrEP), after exposure as postexposure prophylaxis, and as treatment of infected people for secondary prevention. Considerable research has shed new light on antiviral agents for PrEP and for prevention of secondary HIV transmission. While promising results have emerged from several PrEP trials, the challenges of poor adherence among HIV-negative clients and possible increase in sexual risk behaviors remain a concern. In addition, a broader pipeline of antiviral agents for PrEP that focuses on genital tract pharmacology and safety and resistance issues must be developed. Antiretroviral drugs have also been used to prevent HIV transmission from HIV-infected patients to their HIV-discordant sexual partners. The HIV Prevention Trials Network 052 trial demonstrated nearly complete prevention of HIV transmission by early treatment of infection, but the generalizability of the results to other risk groups - including intravenous drug users and MSM - has not been determined. Most importantly, the best strategy for use of antiretroviral agents to reduce the spread of HIV at either the individual level or the population level has not been developed, and remains the ultimate goal of this area of investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.